Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04425655 · ClinicalTrials.gov registry record · Phase 2
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.
A Phase 2 study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04425655 is a Phase 2 study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 2 participants.
The verdict
NCT04425655, a Phase 2 study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase 2 clinical trial will evaluate the effectiveness and safety of fludarabine in combination with CPX-351 in patients with untreated AML. Patients will receive fludarabine and CPX-351 during Induction 1 and 2 as well as 2 cycles of consolidation therapy.
Interventions
- DRUG Fludarabine
- DRUG Vyxeos
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-08-05 |
| Est. Completion | 2022-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04425655
The ClinicalTrials.gov registry entry for NCT04425655 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fludarabine is the first listed.
NCT04425655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04425655 about?
NCT04425655 is a clinical study titled "Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.". This phase 2 clinical trial will evaluate the effectiveness and safety of fludarabine in combination with CPX-351 in patients with untreated AML. Patients will receive fludarabine and CPX-351 during Induction 1 and 2 as well as 2 cycles of consolidation therapy.
What is the current status of trial NCT04425655?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2020-08-05. Estimated completion is 2022-07-01.
What interventions are being tested in trial NCT04425655?
The interventions under investigation include: Fludarabine (DRUG), Vyxeos (DRUG).
Who is sponsoring clinical trial NCT04425655?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.